Drug Pricing Insurance Coverage and Processing Pharmaceutical Companies 
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Commerce
JUNE 17, 2025
Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. In order to automate and enhance these tasks, AI-driven NLP can assist.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
SEPTEMBER 6, 2023
To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.
Pharma Marketing Network
FEBRUARY 5, 2025
The real challenge lies in ensuring it reaches the right patients at the right time and at an affordable price. This is where pharmaceutical market access comes into play. Pharmaceutical market access refers to the process of ensuring a drug is not only approved but also commercially viable, reimbursed, and accessible to patients.
Pharmaceutical Technology
FEBRUARY 7, 2023
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.
Pharmaceutical Commerce
JUNE 16, 2025
With ongoing policy uncertainty, hubs must prioritize adaptable, resilient designs—focusing on process speed, modularity, data tracking, and selecting partners who can evolve with regulatory change. This momentum becomes the difference between a prescription that gets filled and one that becomes another abandonment statistic.
STAT
MARCH 26, 2024
Novo Nordisk plans to seek coverage by Germany’s public health insurance scheme for the use of its Wegovy drug to cut the risk of strokes and heart attacks, if the extended indication wins European approval , Reuters notes. Meanwhile, the Biosecure Act, designed to reduce U.S.
Expert insights. Personalized for you.
81 
Let's personalize your content